FDA, CISA advise on genomic device software vulnerabilities

While Illumina has yet to receive any reports indicating this vulnerability has been exploited, according to a letter to healthcare providers from the U.S. Food and Drug Administration, bad actors could take control of the devices, alter the software and patient test results or compromise a…

Source: www.healthcareitnews.com – Read more